Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science

Clinical research into classical psychedelics has experienced a rapid revival since the 1990s after decades of near-halt following legal restrictions in the 1970s. Early and recent trials report promising therapeutic signals across a range of conditions — including depression, anxiety associated with life‑threatening illness, obsessive‑compulsive disorder, and addictions — but the field still lacks a cohesive, empirically grounded account of the psychological processes that mediate therapeutic change. In particular, the psychotherapy element that accompanies dosing in modern trials (preparation, supported dosing sessions, and integration) is variably described and has not been systematically manipulated to determine how it contributes to outcomes. Luoma and colleagues propose that contextual behavioural science (CBS) and its clinical application, Acceptance and Commitment Therapy (ACT), provide an especially suitable scientific framework for understanding psychedelic experiences and for guiding psychedelic‑assisted therapy. The paper sets out to map the psychological flexibility model onto phenomenology and findings from psychedelic research, to relate CBS to neuroscientific accounts such as the entropic brain theory, and to suggest empirical and clinical research priorities for integrating CBS principles into psychedelic therapy protocols.

This paper is a conceptual and integrative review rather than a primary empirical study. The investigators synthesise historical and contemporary clinical trial reports, observational and qualitative studies, and relevant neuroscientific theories to build an argument connecting CBS/ACT concepts with psychedelic phenomena. The text summarises published trial outcomes, selected qualitative analyses, psychometric findings (where reported), and experimental studies of cognitive and linguistic effects under psychedelics, then maps these data onto the six psychological flexibility processes used in ACT. The extracted text does not report a systematic search strategy, eligible study criteria, or formal risk‑of‑bias assessment; instead, the authors use illustrative empirical examples and theoretical reasoning to support their position. They integrate clinical trial results (including small RCTs and open trials), observational data, qualitative interviews, and neuroscience models (notably the entropic brain theory), and conclude with a set of recommendations for empirical research that would test CBS‑informed hypotheses in psychedelic contexts.

The review first summarises the contemporary evidence base: multiple small, mostly early‑phase clinical trials and observational studies report promising but preliminary therapeutic effects. Examples cited include an uncontrolled psilocybin pilot for refractory obsessive‑compulsive disorder with acute symptom reductions in nine patients; a smoking cessation pilot reporting 80% abstinence at 6 months in 15 participants (67% at 12 months); reductions in drinking in a small alcohol use disorder trial; and several trials in patients with cancer‑related distress in which psilocybin or LSD produced substantial reductions in anxiety and depression, some effects persisting to 6 months or 12 months. An open trial of 20 patients with treatment‑resistant depression showed marked decreases peaking at 5 weeks and some maintenance through 6 months. The authors highlight repeated findings that the intensity of mystical‑type experiences during dosing predicts a range of positive outcomes (depression, smoking cessation, reduced alcohol use, reductions in end‑of‑life distress). Mapping CBS to psychedelic phenomena, the authors describe how each of the six psychological flexibility processes is reflected in the psychedelic experience and in limited empirical data. For self‑as‑context/flexible perspective taking, they note parallels between reported ego‑dissolution, feelings of unity, and reduced activity in brain networks implicated in the self (default mode network); qualitative reports and ego‑dissolution inventories align with ACT concepts of self‑as‑context. Acceptance is linked to common preparatory instructions to "let go," qualitative reports of surrender, and studies reporting increases in death acceptance or self‑reported acceptance after ayahuasca or psilocybin; these findings are preliminary but concordant with the idea that surviving intense affective material may reduce avoidance. Evidence on present‑moment awareness is mixed: qualitative reports suggest increased mindfulness and aesthetic appreciation, but three studies of ayahuasca showed inconsistent results on standard mindfulness subscales, with only one small sample showing improvements on the Philadelphia Mindfulness Scale. Regarding cognitive defusion, the authors point to the well‑documented ineffability and alterations in language under psychedelics, experimental findings showing broadened semantic activation under LSD, and one ayahuasca study reporting increased decentering 24 hours post‑experience (not replicated in a smaller sample). These observations are interpreted as plausibly reducing rigid language‑based control over behaviour. Values and committed action are discussed together: clinical reports commonly describe shifts in life priorities toward more meaningful, prosocial, or spiritual values, and standardised scales in some trials show increased purpose in life. However, the authors note variability in the durability of behavioural change — some studies report sustained benefits up to 14 months, while others show relapse by three months — underscoring the need to support translation of insights into concrete, values‑consistent actions. At the level of neuroscience, the paper summarises the entropic brain theory (EBT): psychedelics increase brain entropy, disrupting over‑stable patterns of neural activity that may underlie psychopathology and thereby permitting novel reorganisations. The authors argue that CBS can complement EBT by specifying contextual and behavioural selection mechanisms that determine which newly possible patterns become retained adaptive changes after entropy subsides. Finally, the paper provides concrete research recommendations: experimentally vary and study psychotherapy components of preparation, dosing, and integration (with ethical caution); measure psychological flexibility using instruments such as the AAQ‑II, CompACT, and MPFI across timepoints and link these to neural measures; manipulate flexibility processes experimentally; examine individual and cross‑cultural moderators and increase minority participation; employ behavioural tasks informed by Relational Frame Theory before/during/after dosing; and test the role of therapeutic alliance. These proposals are intended to move the field from descriptive to mechanistic and intervention‑optimising research.

The authors interpret their synthesis to mean that CBS, and particularly the psychological flexibility model operationalised in ACT, offers a coherent, empirically oriented framework for understanding and augmenting psychedelic‑assisted therapy. They argue that the contextual emphasis of CBS fits well with the centrality of "set and setting" in psychedelic outcomes, and that CBS language and techniques are well suited to address commonly reported psychedelic phenomena such as ego‑dissolution, ineffability, surrender, and rapid shifts in values and perspective. In positioning their argument relative to earlier research, the paper highlights convergence between CBS accounts of psychological change and neuroscientific models such as the entropic brain theory: psychedelics increase neural variability, and CBS provides behavioural and contextual processes that could shape which novel patterns are reinforced and maintained. The authors stress that although mystical‑type experiences predict outcome in several studies, a behavioural, testable account is needed to understand how those experiences translate into enduring improvements. Limitations acknowledged by the authors include the preliminary and heterogeneous nature of existing clinical data, the lack of systematic trials that manipulate the psychotherapy component, mixed findings on some process measures (for example mindfulness and decentering), and the paucity of diversity in participant samples. They caution that manipulating set and setting carries ethical risks and emphasise the need for carefully controlled experimental designs. The authors recommend a research agenda that includes process measurement and experimental manipulation of ACT/CBS‑relevant variables, integration of behavioural and neurobiological measures, attention to cultural and individual differences, and efforts to improve inclusivity. Clinically, they advocate moving from the current, often loosely described ‘‘psychedelic‑assisted therapy’’ model toward a more explicit ‘‘psychedelic‑assisted psychotherapy’’ in which psychotherapeutic methods are systematically specified, tested, and optimised to sustain acute gains. Methodologically, they encourage CBS researchers to use psychedelics as experimental probes for basic questions about language, self, and flexibility, and for psychedelic researchers to incorporate CBS‑derived measures and interventions to clarify mechanisms and improve long‑term outcomes.